Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
- Author
- NELSON, Mark1 ; AMAYA, Gerardo2 ; VANVEGGEL, Simon9 ; BOVEN, Katia10 ; CLUMECK, Nathan3 ; DA CUNHA, Clovis Arns4 ; JAYAWEERA, Dushyantha5 ; JUNOD, Patrice6 ; TAISHENG LI7 ; TEBAS, Pablo8 ; STEVENS, Marita9 ; BUELENS, Annemie9
[1] Chelsea and Westminster Hospital, St Stephen's Centre, London, United Kingdom
[2] Department of Infectious Diseases, Centro Médico Puerto de Hierro and University of Guadalajara, Jalisco, Mexico
[3] Clinic of Infectious Diseases, Saint-Pierre University Hospital, Brussels, Belgium
[4] Centro Medico São Francisco, Curitiba, Brazil
[5] Division of Infectious Diseases, University of Miami, Miami, FL, United States
[6] Clinique Medicale du Quartier Latin, Montreal, Canada
[7] Beijing PUMC Hospital, Being, China
[8] Division of Infectious Diseases, University of Pennsylvania Hospital, Philadelphia, PA, United States
[9] Janssen Infectious Diseases BVBA, Beerse, Belgium
[10] Janssen Research & Development LLC, Titusville, NJ, United States
ECHO and THRIVE Study Groupst - Source
Journal of antimicrobial chemotherapy (Print). 2012, Vol 67, Num 8, pp 2020-2028, 9 p ; ref : 47 ref
- CODEN
- JACHDX
- ISSN
- 0305-7453
- Scientific domain
- Microbiology, infectious diseases; Pharmacology drugs
- Publisher
- Oxford University Press, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- HBV HCV TMC278 efavirenz hepatic safety hepatitis non-nucleoside reverse transcriptase inhibitors
- Keyword (fr)
- Antirétroviral Antiviral Composé non nucléoside Efavirenz Efficacité traitement Essai clinique phase III Essai clinique Etude double insu Foie Hépatite virale B Hépatite virale C Infection mixte Inhibiteur reverse transcriptase Randomisation Rilpivirine SIDA Sécurité Toxicité Virus hépatite B Virus hépatite C Critère d'inclusion Traitement initial Composé acétylénique Dérivé de la benzoxazine Enzyme Flaviviridae Hepacivirus Hepadnaviridae Immunodéficit Immunopathologie Infection Inhibiteur allostérique Inhibiteur enzyme Nucleotidyltransferases Orthohepadnavirus Pathologie de l'appareil digestif Pathologie du foie RNA-directed DNA polymerase Transferases Virose Virus
- Keyword (en)
- Antiretroviral agent Antiviral Non nucleoside compound Efavirenz Treatment efficiency Phase III trial Clinical trial Double blind study Liver Viral hepatitis B Viral hepatitis C Mixed infection Reverse transcriptase inhibitor Randomization Rilpivirine AIDS Safety Toxicity Hepatitis B virus Hepatitis C virus Inclusion criteria Acetylenic compound Benzoxazine derivatives Enzyme Flaviviridae Hepacivirus Hepadnaviridae Immune deficiency Immunopathology Infection Allosteric inhibitor Enzyme inhibitor Nucleotidyltransferases Orthohepadnavirus Digestive diseases Hepatic disease RNA-directed DNA polymerase Transferases Viral disease Virus
- Keyword (es)
- Antiretroviral Antiviral Compuesto no nucleósido Efavirenz Eficacia tratamiento Ensayo clínico fase III Ensayo clínico Estudio doble ciego Hígado Hepatitis vírica B Hepatítis virica C Infección mixta Inhibitor reverse transcriptase Aleatorización Rilpivirina SIDA Seguridad Toxicidad Hepatitis B virus Hepatitis C virus Compuesto acetilénico Benzoxazina derivado Enzima Flaviviridae Hepacivirus Hepadnaviridae Inmunodeficiencia Inmunopatología Infección Inhibidor alostérico Inhibidor enzima Nucleotidyltransferases Orthohepadnavirus Aparato digestivo patología Hígado patología RNA-directed DNA polymerase Transferases Virosis Virus
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02S Antibiotics. Antiinfectious agents. Antiparasitic agents
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02D Viral diseases of the lymphoid tissue and the blood. Aids
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02G Viral hepatitis
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B06 Immunopathology / 002B06D Immunodeficiencies. Immunoglobulinopathies / 002B06D01 Immunodeficiencies
- Discipline
- Immunopathology Infectious pathology Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 26163617
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1093/jac/dks130 
https://dx.doi.org/10.1093/jac/dks130
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1093\/jac\/dks130\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:205:\"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials\";s:9:\"\u0000*\u0000jtitle\";s:45:\"Journal of antimicrobial chemotherapy (Print)\";s:9:\"\u0000*\u0000stitle\";s:33:\"J. antimicrob. chemother. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"67\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2020\";s:8:\"\u0000*\u0000epage\";s:4:\"2028\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0305-7453\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"NELSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mark\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:14:\"AMAYA, Gerardo\";i:1;s:16:\"VANVEGGEL, Simon\";i:2;s:12:\"BOVEN, Katia\";i:3;s:15:\"CLUMECK, Nathan\";i:4;s:21:\"DA CUNHA, Clovis Arns\";i:5;s:21:\"JAYAWEERA, Dushyantha\";i:6;s:14:\"JUNOD, Patrice\";i:7;s:11:\"TAISHENG LI\";i:8;s:12:\"TEBAS, Pablo\";i:9;s:15:\"STEVENS, Marita\";i:10;s:16:\"BUELENS, Annemie\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JACHDX\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:205:\"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1093\/jac\/dks130\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:205:\"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials\";s:9:\"\u0000*\u0000jtitle\";s:45:\"Journal of antimicrobial chemotherapy (Print)\";s:9:\"\u0000*\u0000stitle\";s:33:\"J. antimicrob. chemother. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"67\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2020\";s:8:\"\u0000*\u0000epage\";s:4:\"2028\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0305-7453\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"NELSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mark\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:14:\"AMAYA, Gerardo\";i:1;s:16:\"VANVEGGEL, Simon\";i:2;s:12:\"BOVEN, Katia\";i:3;s:15:\"CLUMECK, Nathan\";i:4;s:21:\"DA CUNHA, Clovis Arns\";i:5;s:21:\"JAYAWEERA, Dushyantha\";i:6;s:14:\"JUNOD, Patrice\";i:7;s:11:\"TAISHENG LI\";i:8;s:12:\"TEBAS, Pablo\";i:9;s:15:\"STEVENS, Marita\";i:10;s:16:\"BUELENS, Annemie\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JACHDX\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:205:\"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:18:\"10.1093\/jac\/dks130\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1093\/jac\/dks130\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:205:\"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials\";s:9:\"\u0000*\u0000jtitle\";s:45:\"Journal of antimicrobial chemotherapy (Print)\";s:9:\"\u0000*\u0000stitle\";s:33:\"J. antimicrob. chemother. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"67\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2020\";s:8:\"\u0000*\u0000epage\";s:4:\"2028\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0305-7453\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"NELSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mark\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:14:\"AMAYA, Gerardo\";i:1;s:16:\"VANVEGGEL, Simon\";i:2;s:12:\"BOVEN, Katia\";i:3;s:15:\"CLUMECK, Nathan\";i:4;s:21:\"DA CUNHA, Clovis Arns\";i:5;s:21:\"JAYAWEERA, Dushyantha\";i:6;s:14:\"JUNOD, Patrice\";i:7;s:11:\"TAISHENG LI\";i:8;s:12:\"TEBAS, Pablo\";i:9;s:15:\"STEVENS, Marita\";i:10;s:16:\"BUELENS, Annemie\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JACHDX\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:205:\"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1093\/jac\/dks130\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:205:\"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials\";s:9:\"\u0000*\u0000jtitle\";s:45:\"Journal of antimicrobial chemotherapy (Print)\";s:9:\"\u0000*\u0000stitle\";s:33:\"J. antimicrob. chemother. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"67\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2020\";s:8:\"\u0000*\u0000epage\";s:4:\"2028\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0305-7453\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"NELSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mark\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:14:\"AMAYA, Gerardo\";i:1;s:16:\"VANVEGGEL, Simon\";i:2;s:12:\"BOVEN, Katia\";i:3;s:15:\"CLUMECK, Nathan\";i:4;s:21:\"DA CUNHA, Clovis Arns\";i:5;s:21:\"JAYAWEERA, Dushyantha\";i:6;s:14:\"JUNOD, Patrice\";i:7;s:11:\"TAISHENG LI\";i:8;s:12:\"TEBAS, Pablo\";i:9;s:15:\"STEVENS, Marita\";i:10;s:16:\"BUELENS, Annemie\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JACHDX\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:205:\"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1093\/jac\/dks130\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:205:\"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials\";s:9:\"\u0000*\u0000jtitle\";s:45:\"Journal of antimicrobial chemotherapy (Print)\";s:9:\"\u0000*\u0000stitle\";s:33:\"J. antimicrob. chemother. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:2:\"67\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"2020\";s:8:\"\u0000*\u0000epage\";s:4:\"2028\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0305-7453\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"NELSON\";s:10:\"\u0000*\u0000aufirst\";s:4:\"Mark\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:11:{i:0;s:14:\"AMAYA, Gerardo\";i:1;s:16:\"VANVEGGEL, Simon\";i:2;s:12:\"BOVEN, Katia\";i:3;s:15:\"CLUMECK, Nathan\";i:4;s:21:\"DA CUNHA, Clovis Arns\";i:5;s:21:\"JAYAWEERA, Dushyantha\";i:6;s:14:\"JUNOD, Patrice\";i:7;s:11:\"TAISHENG LI\";i:8;s:12:\"TEBAS, Pablo\";i:9;s:15:\"STEVENS, Marita\";i:10;s:16:\"BUELENS, Annemie\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JACHDX\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:205:\"Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus\/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:23:\"Oxford University Press\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
